Breaking News Headlines Today | Ground News

See every side of every news story

neurologylive.com image

News from neurologylive.com

See all of neurologylive.com’s headline news. Compare how the top news stories are covered by left-wing and right-wing news sources.

We’ve discovered 384 headlines written by neurologylive.com during the past 3 months.

Ground News rates neurologylive.com’s media bias as unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

neurologylive.com’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about neurologylive.com

Where is neurologylive.com located?neurologylive.com's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top neurologylive.com News

FDA Expands Indications for Neuraceq®, an Amyloid PET Imaging Agent, to Enhance Diagnosis and Care of Patients with Alzheimer's Disease

FDA · Charleston

FDA Expands Indications for Neuraceq®, an Amyloid PET Imaging Agent, to Enhance Diagnosis and Care of Patients with Alzheimer's Disease

67% Center coverage: 21 sources

New indication added for selection of patients for amyloid-directed therapies See the Story

Scientists Reverse Parkinson’s Symptoms in Mice: ‘We were astonished by the success’

Parkinson's Disease

Scientists Reverse Parkinson’s Symptoms in Mice: ‘We were astonished by the success’

86% Center coverage: 14 sources

FDA Approves New Dosing Schedule For Eli Lilly's Kisunla In Alzheimer's Treatment - Eli Lilly (NYSE:LLY)

Alzheimer's Disease · United States

FDA Approves New Dosing Schedule For Eli Lilly's Kisunla In Alzheimer's Treatment - Eli Lilly (NYSE:LLY)

87% Center coverage: 8 sources

Lilly's Kisunla gets FDA approval for a new dosing schedule that significantly lowers ARIA-E risk while maintaining amyloid plaque reduction.See the Story

Centering Empathy in Parkinson Care by Listening Beyond the Diagnosis: María L. De León, MD

The movement disorder specialist and patient living with Parkinson disease highlighted the need for a more human-centered approach in managing chronic and progressive movement disorders. [WATCH TIME: 6 minutes]Parkinson's Disease · Province of Bolzano - South Tyrol See the Story

Soluble TNF Inhibitor XPro Shows Mixed Results in Phase 2 MINDFuL Trial of Alzheimer Disease

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.Oslo, Norway · Oslo See the Story

Using Veterans Health Data to Gain Insights on Sex Differences in Migraine and Stroke Risk: Elizabeth Seng, PhD

The professor of neurology at Albert Einstein College of Medicine talked about new findings presented at AHS, which suggested that both men and women with migraine can face significantly increased risks of ischemic stroke. [WATCH TIME: 5 minutes]New York City · New York Read Article

Need for More Creative, Head-to-Head Migraine Trials: Jessica Ailani, MD

The director of the MedStar Georgetown Headache Center detailed how creative and comparative clinical trials can drive treatment personalization and strengthen clinical confidence. [WATCH: 4 minutes]Maryland · Maryland Read Article

Gene Key to MS Immune Regulation Discovered

New research has identified the gene Egr-1 as a critical regulator of immune balance, offering hope for autoimmune disease therapies. In a mouse model of multiple sclerosis, loss of Egr-1 led to reduced regulatory T cell activity and heightened inflammation. TInnovation See the Story

FDA Approves Updated Donanemab Labeling, BLA Accepted for Tividenofusp Alfa, Nipocalimab Outperforms FcRn Blockers

Neurology News Network. for the week ending July 12, 2025. [WATCH TIME: 4 minutes]Read Article

Phase 2 Published Data of Oveporexton Shows Broad Improvements of Narcolepsy Type 1 Symptoms

The investigational oral orexin receptor 2-selective agonist oveporexton is designed to restore orexin signaling to address the underlying orexin deficiency that is caused by narcolepsy type 1.United States · United States See the Story

Advancing Research for Cognitive Behavioral Therapy to Treat Nightmares: Lisa Cromer, PhD

The professor of psychology at the University of Tulsa discussed the clinical utility of using CBT to treat nightmares–especially in children with comorbid conditions like ADHD and anxiety–and the latest research her lab is conducting. [WATCH TIME: 4 minutes]Tulsa · Tulsa Read Article

Breaking News Topics Related to neurologylive.com